Tar­get­ing un­der­ly­ing cause of PAH, Cam­bridge spin­out Mor­phogen-IX rais­es about $23M in Se­ries B

Back in the year 2000, a ma­jor mu­ta­tion in fa­mil­ial pul­monary ar­te­r­i­al hy­per­ten­sion (PAH) was dis­cov­ered in the re­cep­tor for BMP9 — and for years sci­en­tists in­ves­ti­gat­ed how this mu­ta­tion caus­es PAH and whether that in­for­ma­tion could be used to treat the de­bil­i­tat­ing dis­ease. This cul­mi­nat­ed in a man­u­script in Na­ture Med­i­cine in 2015, and served as the foun­da­tion for the com­pa­ny Mor­phogen-IX — which on Tues­day said it had raised £18.4 mil­lion ($23.2 mil­lion) in a Se­ries B round of fi­nanc­ing. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER